Table 3. Baseline demographics and characteristics for patients with metastatic renal cell carcinoma in the dose‐expansion phase, by cohort.
Cohort 1: No prior systemic therapy directed at metastatic renal cell carcinoma (mRCC).
Cohort 2: At least one, but no more than two, prior systemic treatment regimens directed at mRCC, with at least one prior therapy being a regimen containing an approved vascular endothelial growth factor (VEGF) pathway inhibitor, and resistance to the most recently received approved VEGF pathway inhibitor.
One patient with ECOG PS 1 enrolled in the study reported a worsening of ECOG PS from 1 to 2 on cycle 1 day 1 pre‐dose.
Heng criteria risk groups: favorable (0 risk factors), intermediate (1–2 risk factors), poor (>3 risk factors), unknown for patients missing any of the individual factors.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.